The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients

NCT04839237 on ClinicalTrials.gov · last registry update 2021-04-09

Withdrawn before anyone was enrolled. Its estimated completion date, 1 December 2020, has passed with no update to the record. Primary outcome, as filed: Weight Change at 3 months. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Xiangya Hospital of Central South University
Sponsor type: Other
Enrollment: 0
Started: 2017-12-01
Primary completion: 2020-12-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight Change at 3 months

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.